Cellectis (CLLS) Cash from Financing Activities (2015 - 2026)
Cellectis (CLLS) recorded quarterly Cash from Financing Activities of -$4.9 million in Q1 2026, down 18.36% quarter-over-quarter from -$4.1 million in Q4 2025, and down 19.8% on a YoY basis from -$6.1 million in Q1 2025.
Cellectis (CLLS) Cash from Financing Activities (2015 - 2026) Analysis & Trends
Cellectis' Cash from Financing Activities history runs 12 years deep, the most recent figure standing at -$4.9 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 19.8% year-over-year to -$4.9 million; the TTM figure through Mar 2026 stood at -$17.6 million (down 124.03% YoY), while the FY2025 annual figure was -$16.8 million, down 118.81% from the prior year.
- Cash from Financing Activities was -$4.9 million for Q1 2026 at Cellectis, down from -$4.1 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $78.5 million in Q2 2024 to a low of -$13.7 million in Q4 2022.
- Historically, Cash from Financing Activities has averaged $8.4 million across 5 years, with a median of $1.7 million in 2023.
- The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities tumbled 862.19% in 2022, then jumped 653.5% in 2023.
- A 5-year view of Cash from Financing Activities shows it stood at -$13.7 million in 2022, then soared by 403.68% to $41.6 million in 2023, then sank by 92.97% to $2.9 million in 2024, then tumbled by 241.54% to -$4.1 million in 2025, then slipped by 18.36% to -$4.9 million in 2026.
- The last three Cash from Financing Activities figures came in at -$4.9 million (Q1 2026), -$4.1 million (Q4 2025), and -$4.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - | -4.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.90 Mn |
| Mar 31, 2026 | -4.90 Mn |
| Dec 31, 2025 | -4.14 Mn |
| Dec 31, 2025 | -4.14 Mn |
| Sep 30, 2025 | -4.26 Mn |
| Sep 30, 2025 | -4.26 Mn |
| Jun 30, 2025 | -4.27 Mn |
| Jun 30, 2025 | -4.27 Mn |
| Mar 31, 2025 | -4.09 Mn |
| Mar 31, 2025 | -4.09 Mn |
| Dec 31, 2024 | 2.93 Mn |
| Dec 31, 2024 | 2.93 Mn |
| Sep 30, 2024 | -4.22 Mn |
| Sep 30, 2024 | -4.22 Mn |
| Jun 30, 2024 | 78.51 Mn |
| Jun 30, 2024 | 78.51 Mn |
| Mar 31, 2024 | 11.90 Mn |
| Mar 31, 2024 | 11.90 Mn |
| Dec 31, 2023 | 41.58 Mn |
| Dec 31, 2023 | 41.58 Mn |